Omeveloxolone
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Apr 1, 2026 → Apr 1, 2028
NCT ID
NCT07444333About Omeveloxolone
Omeveloxolone is a pre-clinical stage product being developed by Biogen for Friedreich's Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07444333. Target conditions include Friedreich's Ataxia.
What happened to similar drugs?
0 of 7 similar drugs in Friedreich's Ataxia were approved
Approved (0) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
3
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444333 | Pre-clinical | Recruiting |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon γ-1b | Amgen | Phase 3 | 40 |
| interferon γ-1b | Amgen | Phase 3 | 40 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 40 |
| varenicline + placebo | Pfizer | Phase 2/3 | 30 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 32 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 32 |
| SGT-212 | Solid Biosciences | Phase 1 | 30 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |